Shanghai New Idea Biomedical Technology Co., Ltd., established on 2011-02-18, Business scope includes biomedical technology and related products,Pharmaceutical Intermediates,chemical reagent,Chemical raw materials and products(Except for dangerous goods)research and development,Medical Device Design,Transfer of self-owned research and development results,And provide relevant technical advice,Technical Services,Technical Support;Pharmaceutical Intermediates(except medicines),chemical reagent,Chemical raw materials and products(Except for dangerous goods)Wholesale,commission agent(except auction)and import and export.(Commodities that do not involve state trade management,Quota involved,of license-managed goods,Apply in accordance with relevant national regulations;Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

Taki (Shanghai) Biotechnology Co., Ltd., established on 2018-09-03, Business scope includes biotechnology(remove human stem cells,Development and application of genetic diagnosis and treatment technology)technology development in the field,Technical Services,technical consulting,technology transfer,Sales of biological reagents for non-clinical diagnosis,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Guangzhou Wondfo Biotech Co., Ltd. engages in the manufacture and sale of biochemical reagents, medical products and diagnostic test kits. It also offers various medical tests, including fertility, infectious disease, sexually transmitted diseases, tumor, drugs of abuse, C-reactive protein analyzer, rapid and immunofluorescent test. The company was founded by Wen Mei Li & Wang Ji Hua in 1992 and is headquartered in Guangzhou, China.

Dashi Pharmaceutical (Guangdong) Co., Ltd., established on 2017-08-22, Business scope includes biotechnology extension services;Sales:laboratory equipment,Instrumentation;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)(The above business scope involves the import and export of goods,Technology Import and Export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Chengdu Bailidot Bio-Pharmaceutical Co., Ltd., established on 2017-02-21, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;medical service;Health food production;Inspection and testing service;Drug import and export;Drug Clinical Trial Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Biochemical product technology research and development;Medical Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

National University Corp. Tokyo Medical & Dental University is a private company headquartered in Japan that operates as an national educational institution for dentistry.

Beijing Meibeita Pharmaceutical Research Co., Ltd., established on 2005-01-25, Business scope includes technology transfer,technology development,Technical Services,technical consulting.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

Shanghai Haoyuan Biomedical Technology Co., Ltd., established on 2009-03-17, Business scope includes licensed projects:Hazardous Chemicals Management(see license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Biomedical Technology,Technology development in the field of information technology,technical consulting,Technical Services,technology transfer,Biopharmaceutical Intermediates(In addition to drugs),Biological reagents for non-clinical diagnosis,Research and development of laboratory equipment and consumables,Sales,Business Management Consulting,Import and export,Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Sichuan Baili Pharmaceutical Co., Ltd., established on 1996-08-23, Business scope includes licensed projects:pharmaceutical production;Health food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Import and export;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Cosmetics Wholesale;Healthy food(prepackaged)Sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Dai Nippon Printing Co., Ltd. engages in the provision of publishing and commercial printing services. It operates through the following segments: Information Communication, Lifestyle and Industrial Supplies, Electronics, and Beverages. The Information Communication segment involves in the manufacture and sale of publications, commercial printing materials, business forms, and educational and publications distribution. The Lifestyle and Industrial Supplies segment offers packaging materials, interior and exterior construction materials, photographic materials, and industrial supplies. The Electronics segment handles precision electronic components and other products. The Beverages segment produces and sells carbonated and non-carbonated beverages. The company was founded on October 9, 1876 and is headquartered in Tokyo, Japan.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Technology) is located in the Beijing Economy-Technology Development Area (BDA), also well known as the "Pharmaceutical Valley". Based on biotechnology platforms, Kawin Technology is committed to become a public company that provides the best healthcare solutions to liver disease for our patients. Since establishment, Kawin Technology has formed strategic partnership with Legend Capital, Haitong Capital and Cybernaut respectively. Kawin Technology is a High & New Technology Enterprise certified by Beijing Municipal Science & Technology Commission. It has also been listed as one of Hundred Pilot Enterprises and Top 100 Most-promising Enterprises by Zhongguancun Technology Park (also know as China’s Silicon Valley).

Liaoning Jiankai Technology Co., Ltd., established on 2016-04-27, Business scope includes general items:Medical Research and Experimental Development,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,synthetic material manufacturing(Free of Hazardous Chemicals),Chemical product production(No licensed chemical products),Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals),Specialty Chemicals Sales(Free of Hazardous Chemicals),Chemical product sales(No licensed chemical products),Synthetic Materials Sales,Technology Import and Export,Import and export,New material technology research and development,Biochemical product technology research and development,Manufacturing of medical packaging materials,Natural science research and experimental development,Engineering and Technology Research and Experimental Development,Research and development of bio-based materials technology,Research and development of bio-based material polymerization technology,Technology intermediary service,Manufacturing of bio-based materials,Sales of bio-based materials,Sales of new organic active materials,Domestic trade agent(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Heidelberg Pharma Research GmbH, part of Heidelberg Pharma AG, is a company headquartered in Ladenburg, Germany, that engages in researching biotechnology. The firm was founded in 2011. Jan Schmidt-Brand is the CEO, in this role since 2004.

Dongguan Hongyi Electronics Co., Ltd., established on 2013-06-09, The scope of business includes processing,production and marketing:electronic product,Electronic Accessories,Hardware,plastic products.(law,Administrative regulations,Except for the projects that the State Council decides to prohibit or stipulate that a license should be obtained)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Bio-Thera Solutions Ltd. engages in the research, development, and production of innovative drugs and biosimilar drugs for the treatment of tumours, autoimmune diseases, cardiovascular diseases, other threats to human life, and major health diseases. The company was founded by Sheng Feng Li on July 28, 2003 and is headquartered in Guangzhou, China.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

SeekGene is a provider of genetic data analysis solutions focused on the development and clinical transformation of single cell sorting assays. The SeekGene operations team has many years of research and clinical service experience, focusing on the application of single-cell sequencing technology in real-world clinical research. Its self-developed high-throughput single-cell transcriptome sequencing kit achieves world-leading performance, and is flexible, simple, economical, and accurate, which can accelerate the clinical transformation of single-cell sequencing technology.